Francois Helle

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/901655/francois-helle-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

53	1,931 citations	23	43
papers		h-index	g-index
60 ext. papers	2,208 ext. citations	6.1 avg, IF	4.4 L-index

#	Paper	IF	Citations
53	Kinetics of SARS-CoV-2-Neutralising Antibodies of Residents of Long-Term Care Facilities <i>Journal of Nutrition, Health and Aging</i> , 2022 , 26, 57-63	5.2	1
52	Humoral anti-SARS-CoV-2 immune response after two doses of Comirnaty vaccine in nursing home residents by previous infection status. <i>Vaccine</i> , 2021 , 40, 531-531	4.1	1
51	Longitudinal Analysis and Comparison of Six Serological Assays up to Eight Months Post-COVID-19 Diagnosis. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	6
50	Neutralizing antibodies directed against SARS-CoV-2 in a population residing in a nursing home and a long-term care unit. <i>Geriatrics and Gerontology International</i> , 2021 , 21, 1066-1068	2.9	1
49	BK Polyomavirus Hijacks Extracellular Vesicles for Transmission. <i>Journal of Virology</i> , 2020 , 94,	6.6	16
48	Intercellular Transmission of Naked Viruses through Extracellular Vesicles: Focus on Polyomaviruses. <i>Viruses</i> , 2020 , 12,	6.2	3
47	Anti-spike, Anti-nucleocapsid and Neutralizing Antibodies in SARS-CoV-2 Inpatients and Asymptomatic Individuals. <i>Frontiers in Microbiology</i> , 2020 , 11, 584251	5.7	61
46	QuantIF: An ImageJ Macro to Automatically Determine the Percentage of Infected Cells after Immunofluorescence. <i>Viruses</i> , 2019 , 11,	6.2	15
45	No correlation between Torque Teno virus viral load and BK virus replication after kidney transplantation. <i>Journal of Clinical Virology</i> , 2019 , 116, 4-6	14.5	9
44	BK polyomavirus in the urine for follow-up of kidney transplant recipients. <i>Clinical Microbiology and Infection</i> , 2019 , 25, 112.e1-112.e5	9.5	3
43	Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry. <i>Journal of Virology</i> , 2018 , 92,	6.6	9
42	Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein. <i>Gastroenterology</i> , 2018 , 154, 211-223.e8	13.3	85
41	Claudin-1, miR-122 and apolipoprotein E transductions improve the permissivity of SNU-182, SNU-398 and SNU-449 hepatoma cells to hepatitis C virus. <i>Journal of Viral Hepatitis</i> , 2018 , 25, 63-71	3.4	1
40	Risk factors for BK virus viremia and nephropathy after kidney transplantation: A systematic review. <i>Journal of Clinical Virology</i> , 2018 , 109, 6-12	14.5	32
39	A Simple and Reliable Strategy for BK Virus Subtyping and Subgrouping. <i>Journal of Clinical Microbiology</i> , 2017 , 55, 1177-1185	9.7	22
38	Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles. <i>Hepatology</i> , 2017 , 65, 1851-1864	11.2	8
37	High association of T1858-G1896 precore mutations with impaired base pairing and high hepatitis B virus DNA levels in HBeAg-negative chronically infected patients. <i>Archives of Virology</i> , 2017 , 162, 1913-1	1320	2

(2013-2017)

36	DHEA prevents ribavirin-induced anemia via inhibition of glucose-6-phosphate dehydrogenase. <i>Antiviral Research</i> , 2017 , 146, 153-160	10.8	4
35	Biology of the BKPyV: An Update. <i>Viruses</i> , 2017 , 9,	6.2	36
34	Ribavirin restores IFNI responsiveness in HCV-infected livers by epigenetic remodelling at interferon stimulated genes. <i>Gut</i> , 2016 , 65, 672-82	19.2	15
33	Phylogenetic analysis of a circulating hepatitis C virus recombinant strain 1b/1a isolated in a French hospital centre. <i>Infection, Genetics and Evolution</i> , 2016 , 40, 374-380	4.5	4
32	Hepatitis C Virus Resistance to Carbohydrate-Binding Agents. <i>PLoS ONE</i> , 2016 , 11, e0149064	3.7	7
31	The kinase-inhibitor sorafenib inhibits multiple steps of the Hepatitis C Virus infectious cycle in vitro. <i>Antiviral Research</i> , 2015 , 118, 93-102	10.8	21
30	Comparative Evaluation of Three Nucleic Acid-Based Assays for BK Virus Quantification. <i>Journal of Clinical Microbiology</i> , 2015 , 53, 3822-7	9.7	9
29	Which therapeutic option for hepatitis C virus genotype 1?. <i>Scandinavian Journal of Gastroenterology</i> , 2015 , 50, 470-8	2.4	2
28	Claudin-6 and Occludin Natural Variants Found in a Patient Highly Exposed but Not Infected with Hepatitis C Virus (HCV) Do Not Confer HCV Resistance In Vitro. <i>PLoS ONE</i> , 2015 , 10, e0142539	3.7	7
27	The expression of HCV-associated host factors is dependent on the hepatoma cell line used in HCV studies. <i>Archives of Virology</i> , 2014 , 159, 527-34	2.6	3
26	Up-regulation of the ATP-binding cassette transporter A1 inhibits hepatitis C virus infection. <i>PLoS ONE</i> , 2014 , 9, e92140	3.7	36
25	Simeprevir for the treatment of hepatitis C virus infection. <i>Pharmacogenomics and Personalized Medicine</i> , 2014 , 7, 241-9	2.1	24
24	In vitro infection of primary human hepatocytes by HCV-positive sera: insights on a highly relevant model. <i>Gut</i> , 2014 , 63, 1490-500	19.2	19
23	Alginate hydrogel protects encapsulated hepatic HuH-7 cells against hepatitis C virus and other viral infections. <i>PLoS ONE</i> , 2014 , 9, e109969	3.7	23
22	EAlkylated oligomaltosides as new alternative preservatives: antimicrobial activity, cytotoxicity and preliminary investigation of their mechanism of action. <i>Journal of Applied Microbiology</i> , 2013 , 115, 977-86	4.7	10
21	Natural selection of adaptive mutations in non-structural genes increases trans-encapsidation of hepatitis C virus replicons lacking envelope protein genes. <i>Journal of General Virology</i> , 2013 , 94, 996-10	00 8 .9	10
20	Disulfide bonds in hepatitis C virus glycoprotein E1 control the assembly and entry functions of E2 glycoprotein. <i>Journal of Virology</i> , 2013 , 87, 1605-17	6.6	38
19	The antimalarial ferroquine is an inhibitor of hepatitis C virus. <i>Hepatology</i> , 2013 , 58, 86-97	11.2	41

18	The end-of-treatment ribavirin concentration predicts hepatitis C virus relapse. <i>Therapeutic Drug Monitoring</i> , 2013 , 35, 791-5	3.2	7
17	Permissivity of primary human hepatocytes and different hepatoma cell lines to cell culture adapted hepatitis C virus. <i>PLoS ONE</i> , 2013 , 8, e70809	3.7	21
16	Strong correlation between liver and serum levels of hepatitis C virus core antigen and RNA in chronically infected patients. <i>Journal of Clinical Microbiology</i> , 2012 , 50, 465-8	9.7	26
15	A new tool to study ribavirin-induced haemolysis. <i>Antiviral Therapy</i> , 2012 , 17, 1311-7	1.6	9
14	Genetic recombination of the hepatitis C virus: clinical implications. <i>Journal of Viral Hepatitis</i> , 2011 , 18, 77-83	3.4	58
13	The hepatitis C virus glycan shield and evasion of the humoral immune response. <i>Viruses</i> , 2011 , 3, 1909	- 36 2	74
12	Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. <i>Journal of Virology</i> , 2010 , 84, 11905-15	6.6	165
11	Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. <i>Journal of Viral Hepatitis</i> , 2009 , 16, 156-67	3.4	66
10	Initiation of hepatitis C virus infection requires the dynamic microtubule network: role of the viral nucleocapsid protein. <i>Journal of Biological Chemistry</i> , 2009 , 284, 13778-13791	5.4	60
9	Ceramide enrichment of the plasma membrane induces CD81 internalization and inhibits hepatitis C virus entry. <i>Cellular Microbiology</i> , 2008 , 10, 606-17	3.9	69
8	Early steps of the hepatitis C virus life cycle. <i>Cellular Microbiology</i> , 2008 , 10, 821-7	3.9	95
7	Hepatitis C virus entry into host cells. <i>Cellular and Molecular Life Sciences</i> , 2008 , 65, 100-12	10.3	111
6	The CD81 partner EWI-2wint inhibits hepatitis C virus entry. <i>PLoS ONE</i> , 2008 , 3, e1866	3.7	82
5	The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. <i>Journal of Virology</i> , 2007 , 81, 8101-11	6.6	169
4	Subcellular localization of hepatitis C virus structural proteins in a cell culture system that efficiently replicates the virus. <i>Journal of Virology</i> , 2006 , 80, 2832-41	6.6	162
3	Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. <i>Journal of Biological Chemistry</i> , 2006 , 281, 25177-83	5.4	132
2	Comprehensive search for intra- and inter-specific sequence polymorphisms among coding envelope genes of retroviral origin found in the human genome: genes and pseudogenes. <i>BMC Genomics</i> , 2005 , 6, 117	4.5	27
1	Anti-Spike, anti-Nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic carriers		12